Breaking

Public HealthFood Insecurity and Mental Health in South Africa Linked in New Survey ● Public HealthDirect-to-Consumer Microbiome Tests Face Regulatory Gaps, Review Finds ● PsychiatryREACH+ trial tests relapse prevention strategies in anorexia nervosa ● Medical InformaticsAToP framework maps EHR Transformer readmission risk to temporal patterns ● Public HealthFemale Health Volunteers in Nepal Show Readiness for Tobacco Cessation Counseling ● HematologyUganda study finds high antifolate resistance in children with sickle cell anaemia ● Infectious DiseaseSMC Sentinel Surveillance Detects Gaps and Emerging Resistance in Northern Kenya ● GeneticsIndirect Genetic Effects in ADHD and ASD Traits Across Development ●

Public HealthFood Insecurity and Mental Health in South Africa Linked in New Survey ● Public HealthDirect-to-Consumer Microbiome Tests Face Regulatory Gaps, Review Finds ● PsychiatryREACH+ trial tests relapse prevention strategies in anorexia nervosa ● Medical InformaticsAToP framework maps EHR Transformer readmission risk to temporal patterns ● Public HealthFemale Health Volunteers in Nepal Show Readiness for Tobacco Cessation Counseling ● HematologyUganda study finds high antifolate resistance in children with sickle cell anaemia ● Infectious DiseaseSMC Sentinel Surveillance Detects Gaps and Emerging Resistance in Northern Kenya ● GeneticsIndirect Genetic Effects in ADHD and ASD Traits Across Development ●

Advertisement

Regulatory Affairs

Clinical evidence, research, and medical intelligence in Regulatory Affairs.

Advertisement

Regulatory Affairs · EMA

EMA updates monthly list of medicines under CHMP review

EMA has refreshed its monthly list of medicines under CHMP evaluation, adding new data fields and expanded procedural details for 2025-2026.

By Dr. A. Nikhil Krishnan, MBBS · Oct 17, 2026 · 5 min read

Regulatory Affairs

Clinical evidence, research, and medical intelligence in Regulatory Affairs.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.

Advertisement

Most Read

Medicine World Foundation Alerts

Daily Clinical Dispatch

Receive peer-screened summaries across 17 clinical specialties delivered to your inbox every morning.

Trending Topics Clinical Keywords

#GLP-1 #Lecanemab #CAR-T #SepsisBundle #Semaglutide #SGLT2 #LongCOVID #AntibioticStewardship #AIDiagnostics #Statins

Advertisement

Advertisement